Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response

Molecular Oncology

Volumn 6, Issue 3, 2012, Pages 360-369

  Chen, Yu Li ^a,b   Chang, Ming Cheng ^a   Huang, Chia Yen ^a,b   Chiang, Ying Cheng ^a,c   Lin, Han Wei ^a   Chen, Chi An ^a   Hsieh, Chang Yao ^a   Cheng, Wen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alpha folate receptor; Apoptosis; Chemotherapy; Ovarian serous carcinoma; Overall survival

Indexed keywords

ALPHA FOLATE RECEPTOR; CASPASE 3; CASPASE 7; CISPLATIN; CYCLOPHOSPHAMIDE; FOLATE RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 5; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS OVARIAN CARCINOMA; TREATMENT RESPONSE; TUMOR CELL;

EID: 84862808121     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.11.010     Document Type: Article

References (41)

1. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3:502-516.
2. Antony A.C. Folate receptors. Annu. Rev. Nutr. 1996, 16:501-521.
3. Armstrong D.K., Bicher A., Coleman R.L., Gibbon D.G., Glenn D., Old L. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum- sensitive ovarian cancer in first relapse. J. Clin. Oncol. 2008, 26. abstract 5500.
4. Boyle P., Maisonneuve P., Autier P. Update on cancer control in women. Int. J. Gynecol. Obstet. 2000, 70:263-303.
5. Berek J.S., Bast R.C. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76:2092-2096.
6. Chang M.C., Chen C.A., Hsieh C.Y., Lee C.N., Su Y.N., Hu Y.H., Cheng W.F. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem. J. 2009, 424:449-458.
7. Chen R.H., Chang M.C., Su Y.H., Tsai Y.T., Kuo M.L. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 1999, 274:23013-23019.
8. Cheng W.F., Huang C.Y., Chang M.C., Hu Y.H., Chiang Y.C., Chen Y.L., Hsieh C.Y., Chen C.A. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br. J. Cancer 2009, 100:1144-1153.
9. Choi S.W., Mason J.B. Folate and carcinogenesis: an integrated scheme. J. Nutr. 2000, 130:129-132.
10. DiSaia P.J., Bloss J.D. Treatment of ovarian cancer: new strategies. Gynecol. Oncol. 2003, 90:S24-S32.
11. Elnakat H., Ratnam M. Role of folate receptor genes in reproduction and related cancer. Front. Biosci. 2006, 11:506-519.
12. Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res. 1998, 146:48-55.
13. Huang C.Y., Cheng W.F., Lee C.N., Su Y.N., Chien S.C., Tzeng Y.L., Hsieh C.Y., Chen C.A. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006, 26:4721-4728.
14. International Federation of Gynecology and Obstetrics Classification and staging of malignant tumours in the female pelvis. Acta Obstet. Gynecol. Scand. 1971, 50:1-7.
15. International Federation of Gynecology and Obstetrics Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am. J. Obstet. Gynecol. 1987, 156:263-264.
16. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. Cancer statistics, 2007. CA. Cancer J. Clin. 2007, 57:43-66.
17. Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: a review of the literature. Humanit. Rep. 1989, 4:1-12.
18. Kane M.A., Elwood P.C., Portillo R.M., Antony A.C., Najfeld V., Finley A., Waxman S., Kolhouse J.F. Influence on immunoreactive folate-binding-proteins of extracellular folate concentration in cultured human cells. J. Clin. Invest. 1988, 81:1398-1406.
19. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., Berkowitz R.S., Cramer D.W., Mok S.C. Osteopontin as a potential diagnostic for ovarian cancer. JAMA 2002, 287:1671-1679.
20. Knutson K.L., Krco C., Erskine C.L., Goodman K., Kelemen L.E., Wettstein P.J., Low P.S., Hartmann L.C., Kalli K.R. T cell immunity to folate receptor alpha is prevalent in women with breast or ovary cancer. J. Clin. Oncol. 2006, 24:4254-4261.
21. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J., Low P.S., Knutson K.L., Hartmann L.C. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 2008, 108:619-626.
22. Lin C.Y., Lin L.Y., Chiang C.K., Wang W.J., Su Y.N., Hung K.Y., Chen P.C. Investigation of the association between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am. J. Gastroenterol. 2010, 105:1354-1363.
23. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., Ramoth L.R., Rosen D.G., Liu J., Hellstrom I., Smith D., Hartmann L., Fishman D., Berchuck A., Schmandt R., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10:3291-3300.
24. Malkasian G.D., Melton L.J., O'Brien P.C., Greene M.H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am. J. Obstet. Gynecol. 1984, 149:274-284.
25. 13 in detergent-resistant complexes from the carcinoma cell lines. J. Cell Sci. 2000, 113:349-357.
26. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., Gallo D., Martinelli E., Ranelletti F.O., Ferrandina G., Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11:298-305.
27. Mok S.C., Chao J., Skates S., Wong K., Yiu G.K., Muto M.G., Berkowitz R.S., Cramer D.W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. 2001, 93:1458-1464.
28. Meyer T., Rustin G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br. J. Cancer 2000, 82:1535-1538.
29. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., Bottero F., Colnaghi M.I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer 1994, 30A:363-369.
30. Pannek J., Partin A.W. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin. Urol. Oncol. 1998, 16:100-105.
31. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand and binding assay. Anal. Biochem. 2005, 338:284-293.
32. Quirk J.T., Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol. Oncol. 2005, 97(2):519-523.
33. Rustin G.J. Tumour markers for ovarian cancer. Eur. J. Cancer 1992, 28:2-3.
34. Rubach M., Szymendera J.J., Kaminska J., Kowalska M. Serum CA 15.3, CEA and ESR patterns in breast cancer. Int. J. Biol. Markers 1997, 12:168-173.
35. Swenerton K.D., Hislop T.G., Spinelli J., LeRiche J.C., Yang N., Boyes D.A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet. Gynecol. 1985, 65:264-270.
36. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E., Hellström I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in the sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA 1999, 96:11531-11536.
37. Tsao P.N., Su Y.N., Li H., Huang P.H., Chien C.T., Lai Y.L., Lee C.N., Chen C.A., Cheng W.F., Wei S.C., Yu C.J., Hsieh F.J., Hsu S.M. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2004, 169:505-511.
38. Terry K.L., Sluss P.M., Skates S.J., Mok S.C., Ye B., Vitonis A.F., Cramer D.W. Blood and urinemarkers for ovarian cancer: a comprehensive review. Dis. Markers 2004, 20:53-70.
39. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74:193-198.
40. U.S. Cancer Statistics Working Group. United States Cancer statistics: 2007 incidence and Mortality. Available at: . http://www.cdc.gov/uscs.
41. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., Kennedy A.W., Belinson J., Markman M., Casey G. Lysophosphatidic acid as a potent biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280:719-723.